No one really knows if presidential candidate Hillary Clinton has a position in the market. What the investment community does know is that Clinton's tweet about pharmaceuticals price gouging gave traders an excuse to punish biotechnology stocks and ETFs.
There was, however, at least one outlier.
By the time the closing bell rang on Monday, the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD) was on of the day's top-performing ETFs on a percentage basis, finishing higher by 16 percent. That was enough to make LABD, still in its infancy following its May debut, one of the day's top-performing ETFs of any stripe. LABD and its bullish relative, the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU), were the first triple-leveraged biotech ETFs to come to ...
/www.benzinga.com/general/biotech/15/09/5857273/investors-in-this-biotech-etf-must-have-loved-hillary-clintons-tweet alt=Investors In This Biotech ETF Must Have Loved Hillary Clinton's Tweet>Full story available on Benzinga.com
More...